Press releases
2024
21 Mar 2024, 07:00 | Regulatory
Company delivered significant progress across commercial and R&D priorities
22 Feb 2024, 15:00
2 Feb 2024, 07:00 | Regulatory
· Strong revenue generation in Q4 2023 including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain
· Encouraging results from first-in-human trial of HNSA-5487
· Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s SRP-9001 in DMD
6 Jan 2024, 14:00 | Regulatory
· Strong revenue generation in Q4 2023, including SEK 43m in Idefirix[®] product sales supported by growth in new markets such as U.K., Germany, and Spain
· Encouraging first results from first-in-human trial of HNSA-5487, Hansa’s lead candidate from the NiceR program for repeat dosing
· Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s SR…
2023
14 Dec 2023, 20:00 | Regulatory
Statistically significant reduction in donor-specific antibodies (DSAs) observed among imlifidase patients within five days of treatment as compared to standard of care
13 Dec 2023, 07:00 | Regulatory
7 Dec 2023, 07:00
5 Dec 2023, 13:05 | Regulatory